← Back to all protocols
1

Acute Coronary SyndromeCardiac

1 · ED Quick Pathway

Suspected ACS
↓
12-lead ECG within 10 minutes of arrival
↓
Determine: STEMI / STEMI-equivalent requiring immediate reperfusion — OR — NSTE-ACS
↓
Assess: haemodynamic stability · ongoing/refractory ischaemic pain · cardiogenic shock · arrhythmia · heart failure/pulmonary oedema · bleeding risk · current anticoagulant use · previous intracranial haemorrhage · prior stroke/TIA · age · weight · renal function · planned PCI · potential need for CABG

2 · STEMI — Immediate ED Management

STEMI identified
↓
Activate cath lab / arrange immediate transfer for primary PCI
↓
Aspirin 162–325 mg chewed
↓
P2Y12 inhibitor per the PCI pathway (see Section 5)
↓
Anticoagulation per the PCI strategy (see Section 10)
↓
High-intensity statin
↓
Nitroglycerin if appropriate
↓
Analgesia if required
↓
Immediate transfer for reperfusion — do not let medication administration delay reperfusion

3 · NSTE-ACS — Risk Stratification

NSTE-ACS confirmed
↓
Assess: ongoing ischaemia · dynamic ECG changes · troponin trend · haemodynamic instability · heart failure · ventricular arrhythmia · GRACE/high-risk features · bleeding risk
↓
Very high-risk / unstable → immediate invasive strategy — coordinate P2Y12 and anticoagulation timing directly with the PCI/cardiology team
↓
High-risk but stable → early invasive strategy — avoid routine P2Y12 pretreatment before coronary anatomy is known unless specifically indicated
↓
Lower-risk → ischaemia-guided or selective invasive approach per cardiology assessment

4 · Aspirin

  • Loading dose: 162–325 mg PO chewed
  • Maintenance: 75–100 mg PO daily, unless contraindicated
  • Contraindications/precautions: true severe aspirin allergy · active major bleeding · other clinician-determined contraindication
  • Do not unnecessarily withhold aspirin for minor bleeding risks

5 · P2Y12 Inhibitor — Comparison

DrugLoading doseMaintenance doseWhen to useImportant cautions
Ticagrelor180 mg PO90 mg PO BIDACS patients, particularly when PCI is planned/appropriateDyspnoea, bleeding, bradyarrhythmia; avoid in active bleeding; check contraindications
Prasugrel60 mg PO10 mg PO dailyACS proceeding to PCI when appropriateDo NOT use with prior stroke/TIA; generally avoid ≥75y unless compelling; consider 5 mg maintenance <60 kg
Clopidogrel600 mg PO (PCI strategy)75 mg PO dailyWhen ticagrelor/prasugrel contraindicated, unavailable, not tolerated, or otherwise selectedSlower, less potent platelet inhibition; CYP2C19 interaction/genetic variability

6 · Ticagrelor

  • Loading: 180 mg PO once
  • Then: 90 mg PO twice daily
  • Potent oral P2Y12 inhibitor; appropriate option in ACS, particularly when PCI is planned; rapid onset; does not require metabolic activation
  • Cautions: active pathological bleeding · previous intracranial haemorrhage · significant bradyarrhythmia risk · dyspnoea · drug interactions · assess bleeding risk
  • Patients should generally receive aspirin as part of dual antiplatelet therapy (DAPT) alongside ticagrelor unless there is a specific reason not to

7 · Prasugrel

  • DO NOT GIVE PRASUGREL IF: previous stroke or TIA
  • Loading: 60 mg PO once
  • Then: 10 mg PO daily
  • Selected patients: 5 mg PO daily may be used when appropriate, particularly in lower body-weight patients or older patients according to clinical circumstances
  • Generally avoid routine use in patients ≥75 years unless there is a compelling indication
  • Use caution with body weight <60 kg — increased bleeding risk
  • Intended for patients in whom PCI is planned/being performed, rather than routine pretreatment of undifferentiated NSTE-ACS — particularly relevant once coronary anatomy/PCI strategy is established

8 · Clopidogrel

  • PCI loading: 600 mg PO once
  • Then: 75 mg PO daily
  • May be selected when: ticagrelor contraindicated · prasugrel contraindicated · ticagrelor/prasugrel unavailable · intolerance · high bleeding-risk situations where a less potent P2Y12 strategy is chosen · other clinical circumstances determined by cardiology
  • Clopidogrel is not equivalent in potency to ticagrelor or prasugrel

9 · NSTE-ACS P2Y12 Pretreatment — Important Caution

  • Do not automatically pretreat all NSTE-ACS patients with a P2Y12 inhibitor before coronary anatomy is known
  • For NSTE-ACS patients proceeding to an early invasive strategy, routine pretreatment with a P2Y12 inhibitor before coronary anatomy is known is not universally recommended — the patient may require CABG, and pretreatment increases bleeding and may delay surgery
  • Discuss timing of P2Y12 therapy with the cardiology/PCI team when early angiography is planned
  • This is distinct from STEMI patients being transferred for immediate PCI, where the P2Y12 strategy follows the PCI pathway without delay

10 · Anticoagulation in ACS

  • Anticoagulation is selected according to the clinical scenario and intended invasive/revascularisation strategy
  • Unfractionated heparin (UFH) for PCI: 70–100 units/kg IV bolus, with dosing/ACT monitoring per the PCI protocol
  • If a GP IIb/IIIa inhibitor is being used: 50–70 units/kg IV with ACT-guided adjustment
  • Not every patient needs both UFH and enoxaparin — select one anticoagulation strategy per the planned pathway

11 · Enoxaparin

  • NSTE-ACS, if enoxaparin is the selected anticoagulant: 1 mg/kg SC every 12 hours
  • Severe renal impairment: 1 mg/kg SC every 24 hours
  • Dose according to renal function and local protocol
  • STEMI with fibrinolysis, age <75 years: 30 mg IV bolus, then 1 mg/kg SC every 12 hours — maximum first two SC doses 100 mg
  • STEMI with fibrinolysis, age ≥75 years: no IV bolus — 0.75 mg/kg SC every 12 hours — maximum first two SC doses 75 mg
  • For severe renal impairment, use the appropriate renal-adjusted regimen

12 · Enoxaparin Before Cath-Lab Transfer

  • Do NOT automatically give enoxaparin simply because the patient is going to the cath lab
  • Determine: STEMI vs NSTE-ACS · PCI vs fibrinolysis · what anticoagulant has already been given · last dose/time · renal function · bleeding risk · planned PCI strategy
  • If enoxaparin is the selected anticoagulant strategy, use the dosing in Section 11
  • For a patient already adequately anticoagulated with enoxaparin, do not automatically duplicate anticoagulation before PCI
  • Communicate the exact anticoagulant, dose and time given to the receiving PCI team

13 · Fibrinolysis — If Primary PCI Not Achievable

  • Indications: confirmed STEMI where primary PCI cannot be delivered within 120 minutes of diagnosis — bolus within 10 minutes of the decision; inform the ED lead/cardiology regarding transfer for PCI after fibrinolysis
  • Recommended within 12 hours of symptom onset if PCI is not possible, after consulting cardiology
  • Absolute contraindications: previous intracranial haemorrhage · major trauma/surgery/head injury in the past month · GI bleeding in the past month · known bleeding disorder (excluding menses) · known aortic dissection · non-compressible punctures in the past 24h (e.g. liver biopsy, lumbar puncture)
  • Relative contraindications: pregnancy or within 1 week post-partum · refractory hypertension (SBP >180 and/or DBP >110) · infective endocarditis · active peptic ulcer disease
  • First choice — Tenecteplase: single IV bolus over 10 seconds, weight-adjusted: 30 mg (6000 IU, 6 mL) if <60 kg · 35 mg (7000 IU, 7 mL) 60–69 kg · 40 mg (8000 IU, 8 mL) 70–79 kg · 45 mg (9000 IU, 9 mL) 80–89 kg · 50 mg (10,000 IU, 10 mL) if ≥90 kg. Halve the dose if ≥75 years. Do not give through a line containing glucose
  • Alternative — Alteplase: reconstitute two 50 mg vials each in 50 mL water for injection (1 mg/mL); loading 15 mg IV over 3–5 min, then weight-adjusted infusions (1st over 30 min, then 2nd over 60 min) per local protocol
  • Alternative — Streptokinase: 1.5 million units IV over 30–60 min (diluted per local protocol); anaphylactoid reactions are common — contraindicated if previously used or if there is a history of anaphylaxis to it
  • Fibrinolysis-specific P2Y12 co-therapy: clopidogrel is the preferred agent alongside fibrinolysis (ticagrelor/prasugrel are not the standard choice here) — <75 years: 300 mg load, then 75 mg OD; ≥75 years: no load, 75 mg OD
  • Assess response at 60–90 minutes: improving (≥50% ST resolution, haemodynamically/electrically stable) → routine early PCI, ideally within 2–24h. Not improving, or recurrent ischaemia/reocclusion → rescue PCI

14 · High-Intensity Statin

  • Atorvastatin 80 mg PO or Rosuvastatin 20–40 mg PO, unless contraindicated
  • Give early in ACS

15 · Nitroglycerin

  • 0.4 mg SL, repeat every 5 minutes, up to 3 doses, if appropriate
  • Avoid/contraindicated in: hypotension · suspected right ventricular infarction · recent PDE-5 inhibitor use · severe aortic stenosis · other clinically significant contraindications
  • Nitroglycerin does NOT replace reperfusion therapy

16 · Analgesia

  • If severe ongoing pain persists despite appropriate anti-ischaemic treatment, use analgesia cautiously
  • Avoid routine opioid use simply to treat chest discomfort
  • Do not allow analgesia to delay reperfusion or definitive management

17 · Oxygen

  • Do NOT routinely give oxygen to every ACS patient
  • Give supplemental oxygen if: hypoxaemia · respiratory distress · significant heart failure/hypoxia
  • Otherwise routine oxygen is not required

18 · Contraindication Checklist Before Antithrombotic Therapy

  • ☐ Active major bleeding
  • ☐ Previous intracranial haemorrhage
  • ☐ Previous stroke/TIA — especially important for prasugrel
  • ☐ Recent major surgery
  • ☐ Severe thrombocytopenia
  • ☐ Significant anaemia/bleeding
  • ☐ Current anticoagulant use
  • ☐ Renal impairment
  • ☐ Allergy
  • ☐ Possible need for urgent CABG
  • ☐ Age/weight considerations
  • ☐ Drug interactions

19 · ED ACS Medication Quick Reference

MedicationED dose
Aspirin162–325 mg PO chewed
Ticagrelor180 mg PO loading → 90 mg BID
Prasugrel60 mg PO loading → 10 mg daily
Clopidogrel600 mg PO loading → 75 mg daily
UFH for PCI70–100 U/kg IV bolus
Enoxaparin (NSTE-ACS)1 mg/kg SC q12h
Atorvastatin80 mg PO
Rosuvastatin20–40 mg PO
Nitroglycerin0.4 mg SL q5min × 3 if appropriate

20 · Transfer to Cath Lab — Before-Transfer Checklist

  • ☐ ECG reviewed
  • ☐ STEMI/NSTE-ACS classification documented
  • ☐ Cardiology/PCI team activated
  • ☐ Aspirin given unless contraindicated
  • ☐ P2Y12 decision made
  • ☐ Anticoagulation decision made
  • ☐ Exact anticoagulant + dose + time documented
  • ☐ High-intensity statin given
  • ☐ Nitroglycerin if appropriate
  • ☐ IV access
  • ☐ Continuous cardiac monitoring
  • ☐ Defibrillator available if unstable
  • ☐ Blood pressure/haemodynamics assessed
  • ☐ Bleeding risk assessed
  • ☐ Renal function reviewed
  • ☐ Current anticoagulants documented
  • ☐ Allergies documented
  • ☐ Last PDE-5 inhibitor use checked before nitrates
  • ☐ Receiving PCI team informed of all antithrombotic medications and administration times

21 · Important Clinical Warnings

  • ⚠️ Prasugrel: never use in a patient with previous stroke or TIA. Use particular caution in older patients and patients <60 kg
  • ⚠️ NSTE-ACS: do not automatically give a P2Y12 inhibitor before coronary anatomy is known when early angiography/PCI is planned
  • ⚠️ Enoxaparin: do not automatically give an additional dose before PCI if the patient has already received adequate anticoagulation — check drug + dose + time + renal function
  • ⚠️ STEMI: do not delay reperfusion while waiting for laboratory results or medication administration

22 · Pocket Card — ED ACS Algorithm

ACS
↓
ECG within 10 minutes
↓
STEMI vs NSTE-ACS
↓
Activate PCI when indicated
↓
Aspirin
↓
Choose P2Y12 appropriately
↓
Anticoagulate according to strategy
↓
High-intensity statin
↓
Nitrates if appropriate
↓
Monitor
↓
Transfer for definitive management
← Back to all protocols